



**Affinity  
Immuno**

**AffinityImmuno Inc  
101 Belvedere Ave.  
Charlottetown, PE  
Canada  
C1A 6B3**

**Catalog:** ab-94-021 (chicken anti Bevacizumab idiotyp)

**Description:** Chicken polyclonal anti-Bevacizumab idiotyp (IgY)

**Lot:** 21-01-195A

**Product:**

Target:	Bevacizumab idiotyp
Host species:	Chicken
Volume:	100µl
Concentration:	1mg/ml
Total protein:	100µg
Formulation:	PBS, with 0.02% NaN <sub>3</sub> , pH7

**Production:**

Affinity purified over Bevacizumab resin, and then depleted using human IgG resin to remove all non anti-idiotyp reactivity. Specificity tested by comparing binding to Bevacizumab vs human IgG1 (Figure 1 below).


**Isotype:**

Chicken IgY

**Applications:**


ELISA capture, blocking.

### Binding of chicken anti-Bevacizumab idiotypic to Bevacizumab vs human IgG1



**Figure 1, Binding of anti-Bevacizumab is only to the idiotypic and not the whole IgG molecule.** Anti-Bevacizumab idiotypic was tested for binding to Bevacizumab and human IgG1 by indirect ELISA. Bevacizumab or human IgG1 was coated onto ELISA plates at equivalent concentrations and blocked using 2% BSA in PBS. Chicken anti-Bevacizumab idiotypic was diluted to 15ng/ml and applied in triplicate to the coated wells and incubated for 1 hour at room temperature. After washing the wells, peroxidase conjugated detection antibody (Rabbit anti chicken IgY) was applied to the wells at a concentration of 5ng/ml and incubated for 1 hour at room temperature. After a final wash, the wells were developed with TMB and absorbance at 450nm was measured. These results show that the anti-Bevacizumab idiotypic antibody is strongly specific to the Bevacizumab binding site (idiotypic), and has negligible binding to the conserved regions of the IgG1 protein.

## Comparing chicken anti-Bevacizumab idiootype to monoclonal anti-Bevacizumab idiootype in Bevacizumab sandwich ELISA.



**Figure 2. Comparison of a chicken anti-Bevacizumab idiootype and monoclonal anti-Bevacizumab idiootype for use in Bevacizumab capture ELISA.** Each antibody (chicken anti-Bevacizumab idiootype vs. monoclonal antibody) was coated onto polystyrene ELISA plates at equivalent concentrations for comparison in a Bevacizumab capture ELISA. Bevacizumab was spiked into human serum at concentrations from 50ng/ml down to 1.56ng/ml and applied to each ELISA plate in duplicate and incubated for 1 hour at room temperature. After washing, peroxidase conjugated detection antibody (anti-human IgG1) was applied to the wells at a concentration of 650pg/ml and incubated for 1 hour at room temperature. After a final wash, the wells were developed with TMB and absorbance at 450nm was measured. These results show that the chicken anti-Bevacizumab idiootype antibody performs better as a capture antibody than the competing monoclonal antibody and provides a lower limit of detection.